Form D · Biotechnology

Spyre Therapeutics, Inc.

Waltham, MA · CIK 0001636282

Offering snapshot reported Dec 27, 2023 · SEC filing

Reported sold
$180M
Offering amount: $180M
Investors reported
30
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 11, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 27, 2023Initial$180,000,000No comparison30SEC filing
Jul 6, 2023Initial$210,000,248No comparison41SEC filing
Mar 24, 2015Initial$44,000,000No comparison54SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$10.8M
Form D file number
021-500772

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Jefferies LLC2347
Cowen and Company, LLC7616
Stifel, Nicolaus & Company, Incorporated793
Guggenheim Securities, LLC40638
LifeSci Capital LLC168404

Source: Form D, filed Dec 27, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jeffrey W. Albers Director
Jonathan Alspaugh Executive
Scott Burrows Executive
Cortney Caudill Executive
Russell J. Cox Director
George Georgiou Director
Peter Harwin Director
Michael Henderson Director
Heidy King Jones Executive
Tomas Kiselak Director
Alison Lawton Director
David G. Lowe Director, Executive
Ivana Magovcevic Liebisch Director
Armen Shanafelt Director
Henry Skinner Director
Hunter C, Smith Director
Laurie Stelzer Director
Cameron Turtle Director, Executive
Charles N. York Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
221 Crescent Street Building 23, Unit 105
Waltham, MA, 02453